CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Appreciate recently presented Phase III data supporting the efficacy of osimertinib as adjuvant therapy for patients with Stage IB to IIIA non-small cell lung cancer (NSCLC) with an EGFR tumor mutation, and identify patients who may be appropriate for treatment with this novel approach.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately and safely integrate this strategy into clinical practice.
  • Recognize recent FDA approvals and other therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with anti-CTLA-4 antibodies and/or chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC, and discern how these approaches can be optimally employed in patient care.
  • Review recent advances in the use of immune checkpoint inhibitors with or without chemotherapy for extensive-stage small cell lung cancer, and consider how these regimens can be appropriately and safely integrated into treatment algorithms.
  • Recall the clinical relevance of other oncogenic pathways (eg, ALK, ROS1, HER2) in patients with NSCLC, and appreciate available clinical research data guiding the optimal selection and sequencing of therapies.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.25 (audio) and 1 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPLung21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPLung21/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPLung21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPLung21.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Presenting Faculty Members
  
  Joshua Bauml, MD
  Assistant Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Guardant Health, Inivata, Janssen Biotech Inc, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Carevive Systems, Carisma Therapeutics, Clovis Oncology, Janssen Biotech Inc, Merck, Novartis, Takeda Oncology.
  
  Nathan A Pennell, MD, PhD
  Professor, Hematology and Medical Oncology
  Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  Director, Cleveland Clinic Lung Cancer Medical Oncology Program
  Cleveland, Ohio
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, COTA, G1 Therapeutics, Genentech, a member of the Roche Group, Inivata, Merck, Viosera Therapeutics, Xencor; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Lilly, Pfizer Inc.
  
  Lecia V Sequist, MD, MPH
  Director, Center for Innovation in Early Cancer Detection
  Massachusetts General Hospital Cancer Center
  The Landry Family Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.
  
  Contributing General Medical Oncologists
  
  Spencer Henick Bachow, MD
  Hematologist/Oncologist at Lynn Cancer Institute
  Affiliate Assistant Professor of Medicine at FAU Schmidt College of Medicine
  Boca Raton, Florida
  
  No relevant interests or affiliations to disclose.
  
  Ranju Gupta, MD
  Attending Physician
  Co-Director, Cardio-Oncology Program
  LVPG Hematology Oncology Associates
  Lehigh Valley Health Network
  Bethlehem, Pennsylvania
  
  Speakers Bureau: Lilly.
  
  Zanetta S Lamar, MD
  Florida Cancer Specialists and Research Institute
  Naples, Florida
  
  No relevant interests or affiliations to disclose.
  
  Namrata I Peswani, MD
  Hematologist Oncologist
  Harold C Simmons Comprehensive Cancer Center
  UT Southwestern Medical Center
  Richardson, Texas
  
  No relevant conflicts of interest to disclose.
  
  Syed Farhan Zafar, MD
  Hematologist and Medical Oncologist
  Florida Cancer Specialists and Research Institute
  Chief, Division of Hematology and Oncology
  Lee Health
  Fort Myers, Florida
  
  No relevant interests or affiliations to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: May 2021
  Expiration date: May 2022
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.